medigraphic.com
ISSN 1684-1824 (Electronic)

2021, Number 1

<< Back Next >>

Rev Méd Electrón 2021; 43 (1)

Cholangiocarcinoma: diagnosis, treatment and clinical evolution. Presentation of a case with five-year survival

del Valle LP, Ruesca DC, Ortega CY, Medina CE, Rangel LE, Cora ES

Language: Spanish
References: 16
Page:
PDF size: 120.84 Kb.


ABSTRACT

Cholangiocarcinoma is a malignant tumor originated in the epithelium of the intra or extra hepatic biliary ducts. Pain in the right hypochondrium, jaundice and low weight are the main clinical features. Currently, the diagnosis has been facilitated by the availability of different imaging and endoscopic procedures. The authors presented a case diagnosed with this kind of tumor. The patient underwent surgical, endoscopic and oncologic treatment with gemcitabine, cisplatine and oxaliplatine. He was followed up by a multidisciplinary team and evolved with five-year survival.


REFERENCES

  1. Saha SK, Zhu AX, Fuchs CS, et al. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016 ;21(5):594-9. Citado en PubMed; PMID: 27000463; PMCID: PMC4861366.

  2. Bertuccio P, Bosetti C, Levi F, et al. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013 ; 24(6):1667-74. Citado en PubMed; PMID: 23378539.

  3. Alonso Soto J, Martínez Piti A, Díaz Rondón B, et al. Caracterización de los pacientes con tumores de la vía biliar mediante colangiopancreatografía retrógrada endoscópica. Rev Cubana Med [Internet]. 2016 [citado 29/10/2019]; 55(2): 141-149. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232016000200005

  4. Hidalgo Méndez F. Colangiocarcinoma hiliar (tumor de Klatskin). Rev Clin Med Fam [Internet]. 2014 [citado 29/10/2019 ]; 7(1): 69-2. Disponible en: Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-695X2014000100013

  5. Kumar V, Abbas AK, Aster JC. Oral cavity and gastrointestinal tract. En: Robbins basic pathology[Internet]. 9th ed. Philadelphia: Elsevier; 2013[citado 29/10/2019 ]. p.551-601.Disponible en: Disponible en: https://www.elsevier.com/books/robbins-and-cotran-pathologic-basis-of-disease/kumar/978-1-4557-2613-4

  6. Guillen VS. Revisión sobre colangiocarcinoma y tumor de klatskin. Rev Med Cos Cen [Internet].2016[citado 29/10/2019 ];73(620):533-8.Disponible en: Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=67667

  7. Altekruse SF, Petrick JL, Rolin AI, et al. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States. PLoS One. 2015 ;10(3): e0120574. Citado en PubMed; PMID: 25837669; PMCID: PMC4383424.

  8. Xiang S, Lau WY, Chen XP. Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure. Int J Colorectal Dis. 2015 ;30(2):159-71. Citado en PubMed; PMID: 25376337; PMCID: PMC4304009.

  9. Gonda TA, Viterbo D, Gausman V, et al. Mutation Profile and Fluorescence In Situ Hybridization Analyses Increase Detection of Malignancies in Biliary Strictures. Clin Gastroenterol Hepatol. 2017 ;15(6):913-919.e1. Citado en PubMed; PMID: 28017843.

  10. Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging. 2015 ;42(5):1165-79. Citado en PubMed; PMID: 25447417.

  11. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014 ;60(6):1268-89. Citado en PubMed; PMID: 24681130.

  12. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 2015 ;33(24):2617-22. Citado en PubMed; PMID: 25964250; PMCID: PMC4534524.

  13. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 ;5(6):824-830. Citado en PubMed; PMID: 30998813; PMCID: PMC6567834.

  14. Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol [Internet]. 2017 [citado 20/05/2017];35(15):4006.Disponible en: Disponible en: https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4006

  15. Tanaka A, Tazuma S, Okazaki K, et al. Clinical Features, Response to Treatment, and Outcomes of IgG4-Related Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2017 ;15(6):920-926.e3. Citado en PubMed; PMID: 28111336.

  16. Dudley JC, Zheng Z, McDonald T, et al. Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy. J Mol Diagn. 2016 ;18(1):124-30. Citado en PubMed; PMID: 26596524.




2020     |     www.medigraphic.com